en · de · es
selank-notes.peptides3081.com › News › Origins And Proposed Mechanisms — Complete Guide

Origins And Proposed Mechanisms — Complete Guide

By Editorial Desk · published 2026-05-25 · last reviewed 2026-06-28 · News

If you have been reading about Tuftsin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-06-28. Numbers and descriptions here follow the published literature rather than marketing material.

Origins and Proposed Mechanisms

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Peptide Identity and Structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank at a glance

PropertyValueNotes
Molecular formulaC33H57N11O9Free peptide form
Molecular massAbout 751.9 DaCalculated average mass
Amino acid sequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form TKPRPGP
Structural basisTuftsin analogueExtended version of a natural tetrapeptide
Development originRussian Academy of SciencesWork carried out from the 1980s onward

Mechanism and Evidence Status

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Related pages on this site

Identity and Structural Background

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Selank Background And Chemical Identity

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Further detail

Glutathione S-transferase theta-2 is an enzyme that in humans is encoded by the GSTT2 gene. Glutathione S-transferase (GSTs) theta 2 (GSTT2) is a member of a superfamily of proteins that catalyze the conjugation of reduced glutathione to a variety of electrophilic and hydrophobic compounds. Human GSTs can be divided into five main classes: Alpha, Mu, Pi, Theta, and Zeta. The theta class members GSTT1 and GSTT2 share 55% amino acid sequence identity and both are thought to have an important role in human carcinogenesis. The theta genes have a similar structure, being composed of five exons with identical exon/intron boundaries.

Drug packaging (or pharmaceutical packaging) is process of packing pharmaceutical preparations for distribution, and the physical packaging in which they are stored. It involves all of the operations from production through drug distribution channels to the end consumer. Pharmaceutical packaging is highly regulated but with some variation in the details, depending on the country of origin or the region. Several common factors can include: assurance of patient safety, assurance of the efficacy of the drug through the intended shelf life, uniformity of the drug through different production lots, thorough documentation of all materials and processes, control of possible migration of packaging components into the drug, control of degradation of the drug by oxygen, moisture, heat, light exposure etc., prevention of microbial contamination, sterility, etc. Packaging is often involved in dispensing, dosing, and use of the pharmaceutical product. Communication of proper use and cautionary labels are also regulated. Packaging is an integral part of pharmaceutical product.

== Single particle == In November 2017, an international team of scientists isolated a single proton in a Penning trap in order to measure its magnetic moment to the highest precision to date. It was found to be 2.79284734462(82) nuclear magnetons. The CODATA 2018 value matches this.

Sources: en.wikipedia.org

Background from the literature

=== Cell layers === Transitional epithelium is made up of three types of cell layers: basal, intermediate, and superficial. The basal layer fosters the epithelial stem cells in order to provide constant renewal of the epithelium, and each basal cell contacts the basement membrane. These cells' cytoplasm is rich in tonofilaments and mitochondria; however, they contain few rough endoplasmic reticulum. The tonofilaments play a role in the attachment of the basal layer to the basement membrane via desmosomes. The intermediate cell layer is highly proliferative and, therefore, provides for rapid cell regeneration in response to injury or infection of the organ or tube in which it resides. These cells contain a prominent Golgi apparatus and an array of membrane-bound vesicles. These function in the packaging and transport of proteins, such as keratin, to the superficial cell layer. The cells of the superficial cell layer that lines the lumen are known as facet cells or umbrella cells. This layer is the only fully differentiated layer of the epithelium. It provides an impenetrable barrier between the lumen and the bloodstream, so as not to allow the bloodstream to reabsorb harmful wastes or pathogens. All transitional epithelial cells are covered in microvilli and a fibrillar mucous coat. The epithelium contains many intimate and delicate connections to neural and connective tissue. These connections allow for communication to tell the cells to expand or contract.

Thomas Edison began serious research into developing a practical incandescent lamp in 1878. Edison filed his first patent application for "Improvement in Electric Lights" on 14 October 1878. After many experiments, first with carbon in the early 1880s and then with platinum and other metals, in the end Edison returned to a carbon filament. The first successful test was on 22 October 1879, and lasted 13.5 hours. Edison continued to improve this design and by 4 November 1879, filed for a US patent for an electric lamp using "a carbon filament or strip coiled and connected ... to platina contact wires." Although the patent described several ways of creating the carbon filament including using "cotton and linen thread, wood splints, papers coiled in various ways," Edison and his team later discovered that a carbonized Japanese bamboo filament could last more than 1200 hours. In 1880, the Oregon Railroad and Navigation Company steamer, Columbia, became the first application for Edison's incandescent electric lamps (it was also the first ship to use a dynamo). Albon Man, a New York lawyer, started Electro-Dynamic Light Company in 1878 to exploit his patents and those of William Sawyer. Weeks later the United States Electric Lighting Company was organized. This company made their first commercial installation of incandescent lamps in the fall of 1880, at the Mercantile Safe Deposit Company in New York City, about six months after the Edison incandescent lamps had been installed on the Columbia. Hiram S. Maxim was the chief engineer at the United States Electric Lighting Company.

On Sunday, May 25, 2025, after Filema Duarte still refused to hold elections or resign from office, representative from 117 Cuban Lodges gathered at the National Masonic Temple alongside hundreds of other Freemasons, and demanded his dismissal. Because Filema Duarte had ordered the conference hall to be locked, the Freemasons gathered in the lobby out front of the hall, at the foot of the statue of Carlos Manuel de Céspedes. They sang the National Anthem of Cuba and proceeded to hold the meeting without Filema Duarte or his staff present, and ejected Filema Duarte from the Grand Lodge. Juan Alberto Kessel Linares was reelected as Acting Grand Master of Cuba. Plain-clothes police officers and agents of the State Security Unit were also present at the meeting, capturing photographs and videos of everyone present. Over the course of June, Cuban Freemasons who stood in opposition to Filema Duarte reported that they were under constant surveillance by agents of the government, that their internet was being strategically cut by the government, that power outages were being arranged to target the specific homes of oppositional Freemasons. They also alleged that there were also several "strategic" arrests used as intimidation tactics. On June 14, 2025, Kessel Linares appeared with his Cabinet Elect on the steps of the Grand Lodge of Cuba to hold a press conference, where they denounced the actions of Filema Duarte, of who they said was occupying the office illegally.

Sources: en.wikipedia.org

Further detail

== Medical uses == Seven controlled efficacy trials were conducted of vilazodone for treatment of major depressive disorder. Five of these trials showed no significant influence of vilazodone over placebo on depressive symptoms. In the remaining two trials, small but significant advantages of vilazodone over placebo were found. According to these two eight-week trials in adults, vilazodone has an antidepressant response after one week of treatment. After eight weeks it resulted in a 13% greater response than placebo. Remission rates, however, were not significantly different versus placebo. According to the US Food and Drug Administration (FDA) in 2011, "it is unknown whether vilazodone has any advantages compared to other drugs in the antidepressant class." A 2019 review stated that "present studies do not suggest the superiority of vilazodone compared with other antidepressants." Development of vilazodone for generalized anxiety disorder has been stopped as of 2017. While there is tentative evidence of a small benefit in generalized anxiety disorder, there is a high rate of side effects.

Buckingham Palace announces that King Charles III and Queen Camilla will meet Pope Leo XIV in Vatican City as part of a state visit to Italy in October. MSP Foysol Choudhury is suspended from Scottish Labour over an allegation of inappropriate conduct. 29 September – Chancellor Rachel Reeves makes her keynote speech to the Labour Party Conference. 30 September – Starmer makes his keynote speech to the 2025 Labour Party Conference. Ed Davey reshuffles his Liberal Democrat frontbench.

(See also: Banana equivalent dose) Ingesting Visine, a brand of eye drops, does not cause diarrhea. It is neurotoxic, with consumption causing several serious side effects. Pranks spiking people with Visine rose after the misconception was popularized by the film Wedding Crashers.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank made of?

It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.

Is Selank a naturally occurring substance?

The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.

Which receptors does it act on?

No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.

What is the primary sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.

Network